ASCT2A Salvage Autologous Stem Cell Transplant (ASCT2) Induces Superior Overall Survival Following Bortezomib-Containing Re-Induction Therapy for Relapsed Multiple Myeloma (MM): Results from the Myeloma X (Intensive) Trial
Authors
Cook, GWilliams, C
Cairns, D
Hockaday, A
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Pratt, G
Chown, S
Heartin, E
O'Connor, S
Ashcroft, J
Brown, J
Morris, C
Affiliation
University of Leeds, LeedsIssue Date
2015